Sally Beauty (SBH) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November ...

Core Viewpoint - Edgewell Personal Care (EPC) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with the consensus outlook indicating a potential impact on its near-term stock price based on actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for November 13, and if the reported figures exceed expectations, the stock may experience upward movement; conversely, a miss could lead to a decline [2]. - The Zacks Consensus Estimate predicts quarterly earnings of $0.82 per share, reflecting a year-over-year increase of 13.9%, while revenues are expected to reach $536.03 million, marking a 3.6% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 4.55%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Edgewell Personal is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.04%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, with a positive Earnings ESP indicating a higher likelihood of an earnings beat, particularly when combined with a strong Zacks Rank [8][10]. - Edgewell Personal currently holds a Zacks Rank of 4, which, combined with the negative Earnings ESP, complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Edgewell Personal was expected to post earnings of $1.01 per share but only achieved $0.92, resulting in a surprise of -8.91% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Conclusion - While Edgewell Personal does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].

Wall Street expects a year-over-year decline in earnings on lower revenues when Applied Materials (AMAT) reports results for the quarter ended October 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Novembe ...

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Bitfarms Ltd. due to higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The earnings report is expected on November 13, with a consensus estimate of a quarterly loss of $0.02 per share, reflecting a year-over-year change of +77.8%. Revenues are projected to be $83.11 million, an increase of 85.3% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has been revised 50% lower in the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][12]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a negative Earnings ESP of -100.00% for Bitfarms, suggesting analysts have become more pessimistic. The stock currently holds a Zacks Rank of 4, complicating predictions of an earnings beat [12][10]. Historical Performance - In the last reported quarter, Bitfarms was expected to post a loss of $0.01 per share but actually reported a loss of -$0.02, resulting in a surprise of -100.00%. Over the last four quarters, the company has beaten consensus EPS estimates two times [13][14]. Industry Comparison - Viant Technology, another player in the Zacks Technology Services industry, is expected to report earnings per share of $0.13, reflecting a year-over-year change of -13.3%. Revenues are expected to be $85.29 million, up 80.1% from the previous year [18][19].

The market expects Envoy Medical, Inc. (COCH) to deliver a year-over-year increase in earnings on flat revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if t ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Globant (GLOB) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 13. O ...

Core Viewpoint - Innate Pharma S.A. (IPHA) has experienced a downtrend, losing 12.1% over the past week, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which could lead to a bullish trend [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that bears may be losing control [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - Recent upward revisions in earnings estimates for IPHA are a bullish indicator, as they correlate strongly with near-term stock price movements [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 1.5%, indicating analysts expect better earnings than previously predicted [8]. - IPHA holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - INmune Bio, Inc. (INMB) has shown a recent downtrend, losing 11.9% over the past four weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which could lead to a bullish trend for the stock [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that bears may be losing control over the price [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There has been a notable upward trend in earnings estimate revisions for INMB, which is a bullish indicator as it correlates strongly with near-term stock price movements [7]. - The consensus EPS estimate for the current year has increased by 8.2% over the last 30 days, indicating strong agreement among analysts regarding the company's potential for better earnings [8]. - INMB holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Company Overview - GE HealthCare Technologies (GEHC) is a leading global medtech company based in Chicago, operating across four primary segments: Imaging, Ultrasound (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx) [11] - The company has a diversified portfolio that includes advanced medical imaging systems, ultrasound devices, monitoring equipment, and a growing radiopharmaceuticals pipeline [11] - GEHC aims to deliver precision care by transitioning from a traditional equipment vendor to an integrated solutions provider, combining hardware, software, digital analytics, and pharmaceuticals [11] Investment Ratings - GEHC currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B [12] - The company has a Momentum Style Score of A, indicating strong upward price trends, with shares up 0.6% over the past four weeks [12] - Five analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.03 to $4.56 per share [12] Performance Metrics - GEHC boasts an average earnings surprise of +11.1%, suggesting a strong performance relative to expectations [12] - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, GEHC is positioned as a noteworthy investment opportunity [13]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, helping investors select stocks with high potential for market outperformance [2] Zacks Style Scores Overview - The Style Scores categorize stocks based on value, growth, and momentum characteristics, assigning ratings from A to F, with A indicating the highest potential for outperformance [3] - The Value Score identifies attractive stocks using financial ratios like P/E and Price/Sales, appealing to value investors [3] - The Growth Score focuses on a company's future prospects, analyzing earnings and sales growth to find sustainable growth stocks [4] - The Momentum Score helps investors capitalize on price trends by analyzing recent price changes and earnings estimate revisions [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize returns [10] Stock Highlight: Zoom Video Communications - Zoom Video Communications is currently rated 2 (Buy) on the Zacks Rank and has a VGM Score of B, benefiting from increased demand for remote work solutions [12] - The stock has a Momentum Style Score of B, with shares rising 4.7% over the past four weeks, and an upward revision in earnings estimates for fiscal 2026 [13] - The Zacks Consensus Estimate for Zoom's earnings has increased by $0.02 to $5.83 per share, with an average earnings surprise of +8.7% [13]